Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects-Reference-Cited by-同舟云学术

Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects

Published:2013-09-20 Issue:8 Volume:34 Page:431-441
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Kadokura Takeshi¹,Kashiwa Makoto¹,Groenendaal Dorien²,Heeringa Marten²,Mol Roelof²,Verheggen Frank²,Garcia-Hernandez Alberto²,Onkels Hartmut²

Affiliation:

1. Astellas Pharma Inc; 3-17-1, Hasune, Itabashi-ku; Tokyo; 174-8612; Japan

2. Astellas Pharma Global Development Europe; Sylviusweg 62, PO Box 344; 2300 AH; Leiden; the Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/bdd.1858/fullpdf

Reference25 articles.

1. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy;Ansell;Chest,2004

2. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis;Reynolds;Chest,2004

3. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation;Hart;Ann Intern Med,2007

4. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy;Geerts;Chest,2004

5. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery;Eriksson;J Thromb Haemost,2007

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and development of Factor Xa inhibitors (2015–2022);Frontiers in Pharmacology;2023-02-21

2. Direct Oral Anticoagulants and Vitamin K Antagonists: Role in Thrombotic Damage, Safety, and Indications;Art and Challenges Involved in the Treatment of Ischaemic Damage;2022-10-12

3. Pharmacokinetic-Pharmacodynamic Analysis’ Role in Design of Phase ⅠClinical Trials of Anticoagulant Agents: A Systematic Review;Expert Review of Clinical Pharmacology;2020-10-27

4. New direct oral anticoagulances - new molecules in research;Klinická farmakologie a farmacie;2020-07-16

5. New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds;Expert Opinion on Investigational Drugs;2017-12-14